Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$32.76 - $39.56 $163,800 - $197,800
-5,000 Reduced 34.58%
9,458 $330,000
Q2 2022

Aug 15, 2022

BUY
$8.52 - $25.26 $123,182 - $365,209
14,458 New
14,458 $164,000
Q1 2022

May 16, 2022

SELL
$19.89 - $43.18 $497,250 - $1.08 Million
-25,000 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$26.75 - $46.02 $668,750 - $1.15 Million
25,000 New
25,000 $1.09 Million

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $617M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Lmr Partners LLP Portfolio

Follow Lmr Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Lmr Partners LLP with notifications on news.